glp 1 and substance use disorder disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence remains preliminary, growing preclinical, observational, early clinical data suggest these drugs may reduce glp-1 fatty liver toxicity BLOG Flavor:Blu Raz

glp 1 and substance use disorder disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence remains preliminary, growing preclinical, observational, early clinical data suggest these drugs may reduce glp-1 fatty liver toxicity BLOG Flavor:Blu Raz

glp-1 fatty liver toxicity The future of incretins in the treatment of obesity and non-alcoholic liver disease Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A –

Neuropsychiatric reactions including suicidal thoughts have been reported with GLP analogs, although barely exceeding placebo and unlikely to warrant clinical concern (O'Neil et al, 2017)

BLOG

Flavor:Blu Raz

doi: 10.1186/s13098-017-0289-y